Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements, and we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested to do so by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... hardest substance in the human body is moved by its ... a schnitzel, enormous strengths are working on the surface of ... also goes for dentures, inlays or bridges", glass chemist Prof. ... (Germany) says. After all, these are worn as much as ...
... 2012 Tengion, Inc. (NASDAQ: TNGN ... it has completed the relocation of its corporate ... existing facility in Winston-Salem, North Carolina.  The relocation ... which was designed to fund the Company,s lead ...
... Jan. 5, 2012  Superior Controls, Inc. has been ... Control Engineering magazine.  Each year, the worldwide competition ... exceptional technical expertise, business skills and customer satisfaction. ... 50 applications from industrial systems integrators throughout the ...
Cached Biology Technology:Nanocrystals make dentures shine 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 3Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 4Superior Controls of Seabrook, NH Named System Integrator of the Year for 2012 by Control Engineering Magazine 2
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... raging this summer and some of the smoke from those ... image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... smoke has descended over the Great Lakes region of the ... image from July 23, 2014 (first image feature highlighted below) ... off southeastward. In the image, it is over Manitoba ...
(Date:7/25/2014)... online in the International Journal of Cancer ... cervical cancer based on findings showing successful reduction in ... discrete population of cells in the cervix. , ... squamocolumnar junction cells, or SCJ cells. These cells reside ... the origins of cervical cancer. A research team co-led ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2
... FARMINGTON, Conn., April 23, 2012 /PRNewswire-iReach/  -- Global ... Early Bird discounted registration for three important Boston healthcare ... Pioneers from across the rapidly maturing kinase ... of what lies ahead at the Next-Gen Kinase ...
... annual losses of millions of dollars and pose serious challenges ... difficult and expensive. According to T. D. Schowalter, author ... Integrated Pest Management called " Ecology and Management of ... ) in Southern Pine Forests ," preventative measures are most ...
... Biology 2012, Dr. Blake Rasmussen and colleagues presented a ... vs. Whey Protein Ingestion on Muscle Protein Synthesis Following ... that a protein blend (combination of soy, whey and ... muscle. Specifically, the blend of proteins in this study ...
Cached Biology News:Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3New study finds a protein combination is best to consume post-workout for building muscle 2
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... Design with Purpose -- The ... provide the highest level of ... in an affordable, easy-to-use system. ... and workstation guarantees success with ...
EnzChek cellulase substrate *blue fluorescent, 339/452...
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Biology Products: